Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-Cell response compared with cyclosporine-or mycophenolate-treated patients

Transplantation

Volumn 95, Issue 1, 2013, Pages 184-191

  Havenith, Simone H C ^a   Yong, Si La ^a   Van Donselaar Van Der Pant, Karlijn A M I ^a   Van Lier, René A W ^b   Ten Berge, Ineke J M ^a   Bemelman, Fréderike J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

Author keywords

CMV; Everolimus; Kidney transplantation; mTOR inhibitors; T cells

Indexed keywords

BASILIXIMAB; CD27 ANTIGEN; CD28 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIBODY; EVEROLIMUS; IMMUNOGLOBULIN G ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN;

ADULT; ALLOIMMUNITY; ARTICLE; CD27-CD8+ T LYMPHOCYTE; CD28-CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG EFFICACY; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; VIRUS REACTIVATION;

ADULT; AGED; CD8-POSITIVE T-LYMPHOCYTES; CYCLOSPORINE; CYTOMEGALOVIRUS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84872083283     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318276a1ef     Document Type: Article

References (28)

1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715.
2. Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10: 457.
3. Brouard S, Puig-Pey I, Lozano JJ, et al. Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy. Am J Transplant 2010; 10: 2604.
4. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105: 4743.
5. Kang J, Huddleston SJ, Fraser JM, et al. De novo induction of antigenspecific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. J Leukoc Biol 2008; 83: 1230.
6. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002; 8: 379.
7. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460: 108.
8. Turner AP, Shaffer VO, Araki K, et al. Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. Am J Transplant 2011; 11: 613.
9. Struijk GH, Minnee RC, Koch SD, et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney Int 2010; 78: 934.
10. Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011; 11: 2453.
11. Nashan B, Gaston R, Emery V, et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012; 93: 1075.
12. Bemelman FJ, de Maar EF, Press RR, et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation 2009; 88: 421.
13. Kuijpers TW, Vossen MT, Gent MR, et al. Frequencies of circulating cytolytic, CD45RA+CD27-, CD8+ T lymphocytes depend on infection with CMV. J Immunol 2003; 170: 4342.
14. van Leeuwen EM, Remmerswaal EB, Vossen MT, et al. Emergence of a CD4+. J Immunol 2004; 173: 1834.
15. van de Berg PJ, van SA, ten Berge IJ, et al. A fingerprint left by cytomegalovirus infection in the human T cell compartment. J Clin Virol 2008; 41: 213.
16. Uss E, Yong SL, Hooibrink B, et al. Rapamycin enhances the number of alloantigen-induced human CD103+CD8+ regulatory T cells in vitro. Transplantation 2007; 83: 1098.
17. Strippoli GF, Hodson EM, Jones C, et al. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81: 139.
18. Brennan DC, Garlock KA, Lippmann BA, et al. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1997; 8: 118.
19. van Lier RA, ten Berge IJ, Gamadia LE. Human CD8(+) T-cell differentiation in response to viruses. Nat Rev Immunol 2003; 3: 931.
20. Remmerswaal EB, Havenith SH, Idu MM, et al. Human virus-specific effector-type T cells accumulate in blood but not in lymph nodes. Blood 2012; 119: 1702.
21. Ferrer IR, Araki K, Ford ML. Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant 2011; 11: 654.
22. Ferrer IR, Wagener ME, Robertson JM, et al. Cutting edge: rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J Immunol 2010; 185: 2004.
23. Slavik JM, Lim DG, Burakoff SJ, et al. Uncoupling p70(s6) kinase activation and proliferation: rapamycin-resistant proliferation of human CD8(+) T lymphocytes. J Immunol 2001; 166: 3201.
24. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107: 4781.
25. Darrah PA, Patel DT, De Luca PM, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13: 843.
26. Nebbia G, Mattes FM, Smith C, et al. Polyfunctional cytomegalovirusspecific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am J Transplant 2008; 8: 2590.
27. Boom R, Sol C, Weel J, et al. A highly sensitive assay for detection and quantitation of human cytomegalovirus DNA in serum and plasma by PCR and electrochemiluminescence. J Clin Microbiol 1999; 37: 1489.
28. Lamoreaux L, Roederer M, Koup R. Intracellular cytokine optimization and standard operating procedure. Nat Protoc 2006; 1: 1507.